Lung Cancer
Durvalumab/Tremelimumab/Chemotherapy Combination Approved for NSCLC Indication
November 15, 2022
Article
The FDA has given the go-ahead to a combination of tremelimumab-actl (Imjudo) plus durvalumab (Imfinzi) and platinum-based chemotherapy for patients with non-small cell lung cancer and no EGFR mutations or ALK aberrations.
Ahulwalia on Targeting the Blood Brain Barrier With Novel Immunotherapies and Precision Oncology
November 11, 2022
Video
Manmeet Ahulwalia, MD, MBA, underscores how novel treatment approaches in oncology are proving effective in managing brain metastases.
Maximizing Potential of Immunotherapy Requires Appropriate irAE Management
November 10, 2022
Article
Immunotherapy has changed the face of cancer treatment, but requires appropriate irAE management to reach full potential.
Cemiplimab Gets Go Ahead In Combination With Chemotherapy For Advanced NSCLC
November 09, 2022
Article
Cemiplimab, in combination with platinum-based chemotherapy, has been approved for patients with advanced non–small cell lung cancer with no EGFR, ALK, or ROS1 aberrations.
Oncology Drug Crash Course: Fam-Trastuzumab Deruxtecan-Nxki (Enhertu)
November 08, 2022
Article
After demonstrating significant efficacy as a third-line treatment for patients with metastatic HER2-positive breast cancer, fam-trastuzumab deruxtecan-nxki has gained approval from the FDA for 5 indications and is under investigation across solid tumors.
Novel Intervention Reduces Time to Molecular Testing for Patients With NSCLC In Community Practice Setting
November 07, 2022
Article
A quality improvement project improved the time to molecular testing for patients with newly diagnosed, metastatic non–small cell lung cancer.
Sintilimab/Chemotherapy Regimen Boosts Progression-Free Survival in EGFR-Mutated NSCLC
November 05, 2022
Article
After 13.1 months of follow-up, the median progression-free survival in patients with EGFR-mutant non–small cell lung cancer who received a sintilimab-based regimen was 5.5 months.
Nurse Leaders Must Foster Change to Develop a Healthy Workplace Environment
October 20, 2022
Article
Linda Laskowski-Jones, MS, APRN, ACNS-BC, CEN, NEA-BC, FAAN, discusses how oncology nurse leaders can help improve working environments for their staff.
Promising Selpercatinib Data Highlight Value of RET Fusion Testing for Patients With Solid Tumors
October 17, 2022
Article
Selpercatinib demonstrated a promising efficacy profile in patients with RET-fusion positive solid tumors.
Avelumab/Axitinib Combo May Unlock New Treatment Direction for Rare Thymic Epithelial Tumors
October 16, 2022
Article
Phase 2 findings indicate that a combination of avelumab and axitinib may draw promising responses in patients with advanced type B3 thymoma and thymic carcinoma.